---
title: "Follistatin-344"
canonical_url: https://peptidelibrary.app/library/follistatin-344
description: "Isoform of follistatin that binds myostatin/activin. Gene-therapy and research-peptide forms exist; no FDA-approved follistatin drug. WADA prohibits myostatin inhibitors (S4)."
updated: 2026-09-06
publisher: Peptide Library
notice: "Research and educational use only. Not medical advice."
---

# Follistatin-344

Follistatin-344 (also called FST-344 or Follistatin isoform 344) is a myostatin-binding glycoprotein in the Myostatin inhibitor class. Follistatin-344 is a glycoprotein that acts as a high-affinity binding trap for TGF-beta superfamily ligands, most importantly myostatin and activin A.

Isoform of follistatin that binds myostatin/activin. Gene-therapy and research-peptide forms exist; no FDA-approved follistatin drug. WADA prohibits myostatin inhibitors (S4).

Also known as: FST-344, Follistatin isoform 344.

Categories: Fat Loss, Muscle/Recovery, Experimental.

## Classification

- Type: Myostatin-binding glycoprotein / research
- Mechanism class: Myostatin inhibitor
- Development stage: Research only
- Regulatory class: Research compound, not FDA-approved

## Mechanism

Follistatin-344 is a glycoprotein that acts as a high-affinity binding trap for TGF-beta superfamily ligands, most importantly myostatin and activin A. Myostatin normally restrains skeletal muscle growth by signalling through activin type II receptors and ALK4/5 to activate SMAD2/3; follistatin binds it in the extracellular space so it cannot engage those receptors, relieving the inhibition. In animal models this produces substantial muscle hypertrophy. Two limitations matter: follistatin also neutralises activins with roles in reproduction and inflammation, so the effect is not myostatin-specific, and the 344 isoform binds cell-surface heparan sulfate, which restricts its distribution. There are no controlled human data.

Targets: Myostatin (GDF8), Activin A.

Origin: Recombinant / synthetic glycoprotein isoform.

## Properties

- Molecular formula: Protein (glycoprotein); sequence length 344 aa
- Molecular weight: ≈38–40 kDa (glycosylation dependent)
- CAS number: 1461868-87-4
- Half-life: Varies; protein biologic

## Evidence

- Evidence level: Insufficient Evidence
- Highest documented: None documented
- Human trials: 0
- Controlled human trials: 0
- Preclinical sources: 0

No human dose is established for this compound.

Each step shows whether the sources Peptide Library has reviewed include that kind of research. Counts are reviewed sources, not every study ever published. Reviews and programme summaries that describe human use are shown as "reported", not as trials, and registered trials without published results are listed but not counted. A higher step means research has progressed further; it does not mean a compound works better or is safer. Compounds whose evidence has not been reviewed yet show "Not reviewed" instead of a guess.

### Studies

1. NCT01519349 - Follistatin Gene Transfer to Patients With Becker Muscular Dystrophy. Human study (early or uncontrolled). Population: Patients with Becker muscular dystrophy (n=15). Safety and muscle response. Research on a related compound, not this one. Limitations: Studied an analog, not Follistatin-344 itself [Source](https://clinicaltrials.gov/study/NCT01519349)
2. NCT06411366 - Phase I: Safety and Efficacy of an Injectable Follistatin Plasmid Gene Therapy. Human study (early or uncontrolled). Population: Participants (n=43). Safety and efficacy. Research on a related compound, not this one. Limitations: Studied an analog, not Follistatin-344 itself [Source](https://clinicaltrials.gov/study/NCT06411366)
3. NCT07443826 - CALM-AF-AI: Counteracting Age-related Loss of Muscle With AAV-Follistatin. Human study (early or uncontrolled). Population: Participants (n=12). Age-related loss of muscle. Research on a related compound, not this one. Limitations: Studied an analog, not Follistatin-344 itself; Registered trial with no published results yet. [Source](https://clinicaltrials.gov/study/NCT07443826)

### Registered trials

- [NCT01519349](https://clinicaltrials.gov/study/NCT01519349)
- [NCT06411366](https://clinicaltrials.gov/study/NCT06411366)
- [NCT07443826](https://clinicaltrials.gov/study/NCT07443826)

## Safety

Side effects: Unknown human peptide-vial safety; Theoretical activin-related effects.

Risks: WADA S4 hormone modulator; Not an approved drug.

Human safety basis: No controlled human safety data

Key limitations: No established human dosage.; No controlled human trial results in the reviewed sources.; Not approved by the FDA for any use..

## Regulatory status

Follistatin-344 is not an FDA-approved product. It is sold for laboratory research and has no approved medical use.

- FDA status: Not Approved
- WADA status: Banned in Sport
- Availability: Research-Only

## Frequently asked questions

### What is Follistatin-344?

Isoform of follistatin that binds myostatin/activin. Gene-therapy and research-peptide forms exist; no FDA-approved follistatin drug. WADA prohibits myostatin inhibitors (S4).

### How does Follistatin-344 work?

Follistatin-344 is a glycoprotein that acts as a high-affinity binding trap for TGF-beta superfamily ligands, most importantly myostatin and activin A. Myostatin normally restrains skeletal muscle growth by signalling through activin type II receptors and ALK4/5 to activate SMAD2/3; follistatin binds it in the extracellular space so it cannot engage those receptors, relieving the inhibition.

### Is Follistatin-344 FDA approved?

No. Follistatin-344 is not approved by the FDA for any indication and is categorised as research-only. It has not been reviewed for safety or efficacy as a medicine, and published research should be read as investigation rather than established use.

### What is the half-life of Follistatin-344?

Reported half-life for Follistatin-344 is Varies; protein biologic. Half-life describes how long the compound persists in circulation, not how long any effect lasts, and published figures vary with route of administration, formulation and the population studied.

### Is Follistatin-344 banned in sport?

Follistatin-344 is recorded here as prohibited in sport. Athletes subject to anti-doping rules should check the current WADA Prohibited List directly, since it is revised annually and classifications change.

### What peptides are similar to Follistatin-344?

Compounds most often compared with Follistatin-344 include ACE-031, GDF-11, MGF and AICAR. They are grouped by shared mechanism or research area rather than by equivalence, and their regulatory status and evidence base differ.

## References

- [WADA Prohibited List 2026](https://www.wada-ama.org/en/prohibited-list)
- [Detection of black market follistatin 344 — Drug Test Anal, 2020](https://pubmed.ncbi.nlm.nih.gov/33460286/)
- [Central serous chorioretinopathy associated with high-dose follistatin-344: a retrospective case series — Int Ophthalmol, 2020](https://pubmed.ncbi.nlm.nih.gov/32671599/)
- [Detection of black market follistatin 344 — Drug Test Anal, 2019](https://pubmed.ncbi.nlm.nih.gov/31758732/)
- [The transgenic expression of human follistatin-344 increases skeletal muscle mass in pigs — Transgenic Res, 2017](https://pubmed.ncbi.nlm.nih.gov/27787698/)
- [Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance — Sports Med, 2026](https://pubmed.ncbi.nlm.nih.gov/41966639/)
